Lanreotide U.S. label context · version 1
This page preserves this version's wording and source pins. Open the current profile →
What does the U.S. product label say?
Lanreotide acetate injection · Read September 15, 2026 · Preserved label summary 1
Which population and use does the label cover?
The cited label covers specified acromegaly, gastroenteropancreatic neuroendocrine tumor and carcinoid-syndrome settings. Indications and outcomes differ across those populations. Label: 1 ↗
Which safety limits matter?
Warnings include gallstones and complications, altered glucose control, reduced heart rate, thyroid abnormalities, and fat malabsorption or steatorrhea. These label risks are distinct from event rates in an individual trial. Label: 1, 5 ↗
Label edition and source pins
U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.
Lanreotide acetate injection · SPL version 3 · published 2025-06-02
Label ZIP SHA-256: 549b28079c4ff34c485706fc6353164f8e1903e90a1ec7f10f97482b441b0bfe. Extracted XML SHA-256: c8c3f515d19dbbec43ebb5353991467b8f96123d3e513e3e183fd915087f874b.